1. Home
  2. TOI vs ALLO Comparison

TOI vs ALLO Comparison

Compare TOI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOI
  • ALLO
  • Stock Information
  • Founded
  • TOI 2007
  • ALLO 2017
  • Country
  • TOI United States
  • ALLO United States
  • Employees
  • TOI N/A
  • ALLO N/A
  • Industry
  • TOI Medical/Nursing Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TOI Health Care
  • ALLO Health Care
  • Exchange
  • TOI Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • TOI 266.8M
  • ALLO 277.8M
  • IPO Year
  • TOI N/A
  • ALLO 2018
  • Fundamental
  • Price
  • TOI $2.39
  • ALLO $1.23
  • Analyst Decision
  • TOI
  • ALLO Strong Buy
  • Analyst Count
  • TOI 0
  • ALLO 9
  • Target Price
  • TOI N/A
  • ALLO $8.44
  • AVG Volume (30 Days)
  • TOI 1.9M
  • ALLO 2.5M
  • Earning Date
  • TOI 08-12-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • TOI N/A
  • ALLO N/A
  • EPS Growth
  • TOI N/A
  • ALLO N/A
  • EPS
  • TOI N/A
  • ALLO N/A
  • Revenue
  • TOI $403,152,000.00
  • ALLO N/A
  • Revenue This Year
  • TOI $23.95
  • ALLO N/A
  • Revenue Next Year
  • TOI N/A
  • ALLO $199.63
  • P/E Ratio
  • TOI N/A
  • ALLO N/A
  • Revenue Growth
  • TOI 17.64
  • ALLO N/A
  • 52 Week Low
  • TOI $0.13
  • ALLO $0.86
  • 52 Week High
  • TOI $3.50
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • TOI 38.68
  • ALLO 44.00
  • Support Level
  • TOI $2.28
  • ALLO $1.27
  • Resistance Level
  • TOI $2.87
  • ALLO $1.51
  • Average True Range (ATR)
  • TOI 0.24
  • ALLO 0.11
  • MACD
  • TOI -0.10
  • ALLO -0.00
  • Stochastic Oscillator
  • TOI 1.24
  • ALLO 17.65

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: